Article Text

Download PDFPDF

#820 Survival associated with the use of one-step nucleic acid amplification (OSNA) to detect SLN metastasis in cervical cancer
  1. Nicolò Bizzarri1,
  2. Camilla Fedele1,
  3. Elena Teodorico1,
  4. Camilla Certelli1,
  5. Luigi Pedone Anchora1,
  6. Vittoria Carbone1,
  7. Valerio Gallotta1,
  8. Anna Fagotti1,
  9. Gian Franco Zannoni2,
  10. Gabriella Ferrandina1,
  11. Giovanni Scambia1 and
  12. Francesco Fanfani1
  1. 1UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
  2. 2Unità di Ginecopatologia e Patologia Mammaria, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy


Introduction/Background Sentinel lymph node (SLN) biopsy is part of surgical treatment of apparent early-stage cervical cancer. SLN is routinely analyzed by ultrastaging and immunohistochemistry. Recently, one-step nucleic acid amplification (OSNA) method has been demonstrated to be an accurate tool to detect SLN metastases in cervical cancer with the advantage of a rapid standardized technique with no sampling bias. Nevertheless, oncological safety of OSNA method in cervical cancer has not been previously explored. The aim of this study was to assess the disease-free survival of patients undergoing SLN analyzed by OSNA compared with ultrastaging.

Methodology Single-center, retrospective, cohort study. Patients undergoing SLN mapping (± pelvic lymphadenectomy) and primary surgery for apparent early-stage cervical cancer between 05/2017 and 01/2021 were included. SLN was analyzed entirely with OSNA or with ultrastaging. Patients with SLN mapping failure, with SLN analyzed alternatively/serially with OSNA and ultrastaging and undergoing neo-adjuvant therapy were excluded. Appropriate statistical tests were used.

Results One-hundred and fifty-seven patients were included, 50 (31.8%) in the OSNA group and 107 (68.2%) in the ultrastaging group. Patients’ characteristics are showed in table 1. The only significant difference between the two groups was the incidence of lymph node metastasis (28.0% versus 10.3% in OSNA versus ultrastaging group, respectively; p=0.009). A trend toward higher incidence of micrometastases detection in OSNA group was noted (table 1). Median follow up time was 41 months (95%CI:37.9–42.2). 5-year DFS in patients undergoing OSNA versus ultrastaging was 87.0% versus 91.0% (p=0.809). No difference in the incidence of lymph node recurrence between the two groups was noted (OSNA 20.0% versus ultrastaging 18.2%, p=0.931).

Abstract #820 Table 1

Characteristics of patients with SLN analyzed by OSNA and ultrastaging.

Conclusion The use of OSNA to entirely assess the presence of SLN metastases in cervical cancer was not associated with worse DFS compared to ultrastaging. Incidence of lymph node recurrence in the two groups was not different.

Disclosures None

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.